en عمومى General پژوهشي Research <span style="font-size:12pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times=""><b>Background: </b>C-peptide determination in the honeymoon phase is a practical approach to start or stop insulin-based treatment in patients suffering from type 1 diabetes (T1DM). The present study aimed to assess the C-peptide levels in plasma at the beginning of type 1 diabetes diagnosis in children during the honeymoon period. </span></span></span><br> <span style="font-size:12pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times=""><b>Methods:</b> Younger than 18 years old children with proven insulin-dependent diabetes who didn&rsquo;t receive any insulin treatment were included in the study. Those related to non-T1DM (T2DM, MODY, and secondary diabetes) and primary insulin administration, were excluded. Totally, 30 patients were entered. Blood samples were collected and C-peptide levels, fasting and random glucose, blood glycosylated hemoglobin (HbA1C), and serum levels of GAD (anti-glutamic acid decarboxylase antibodies), IA-2 (anti-tyrosine phosphatase antibodies), ICA (islet cell antibodies), and IAA (insulin autoantibodies) were analyzed.</span></span></span><br> <span style="font-size:12pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times=""><b>Results:</b> The age of patients had a range of 1 to 17 years old. The honeymoon period had a range between 3 to 18 months. Only 7 out of 30 (23.33%) studied patients had C-peptide levels of <5 before the honeymoon period. Reversely, 23 out of 30 (76.66%) patients had C-peptide levels of <5 after the honeymoon period. Additionally, IAA, ICA, GAD, and TA2 autoantibodies were detected in 23.33% (7 out of 30 patients), 20% (6 out of 30 patients), 66.66% (20 out of 30 patients), and 23.33% (7 out of 30 patients), respectively.</span></span></span><br> <span style="font-size:12pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times=""><b>Conclusion:</b> These findings may show the high impact and role of GAD autoantibody and also C-peptide during the honeymoon period. </span></span></span><br> &nbsp; C-peptide, Determination, Type 1 diabetes, Children, Honeymoon Phase 84 91 http://intjmi.com/browse.php?a_code=A-10-1-590&slc_lang=en&sid=1 Maryam Nakhaey Moghadam 10031947532846006737 10031947532846006737 No Pediatric endocrinologist, Children and adolescents health research Center, Zahedan Medical University of Medical Sciences Zahedan, Iran. Elham Shafighi Shahri 10031947532846006738 10031947532846006738 Yes Pediatric endocrinologist, Children and adolescents health research Center, Zahedan Medical University of Medical Sciences Zahedan, Iran